Gordon Li, MD

Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)

Clinical Focus

Cancer > Neuro Oncology
Neurosurgery
Brain Tumors
radiosurgery
Minimally Invasive Surgical Procedures

Academic Appointments

Professor - University Medical Line, Neurosurgery
Professor - University Medical Line (By courtesy), Neurology
Professor - University Medical Line (By courtesy), Otolaryngology (Head and Neck Surgery)
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute

Administrative Appointments

Associate Dean, Academic Affairs, Stanford University School of medicine (2022 - Present)
Vice Chair of Faculty Affairs, Department of Neurosurgery, Stanford (2021 - Present)
Assistant Program Director, Stanford University Department of Neurosurgery (2020 - Present)

Honors & Awards

Plummer Linzy Scholarship, University of California, Davis (2000)
Ernest Gold Award, University of California, Davis (2001)
Predoctoral Research Award, University of California, Davis (2001)
Junior AOA, University of California, Davis (2002)
SANS Challenge Finalist, Congress of Neurological Surgeons (2008)
Ruth L. Kirschstein National Research Service Award (PI), NIH-NCI (1F32CA132329-01) (2008-2010)
Center for Brain and Behavior Awards in Pediatric Neurosciences (co-investigator), Lucile Packard Children's Hospital (2009-2011)
Grand Opportunity Grant (co-investigator), NIH (RC2CA148491-01) (2009-2011)
Disease Team Therapy Development Planning Award (Planning Investigator), CIRM (DR2-05373) (2011-2012)
K08 Mentored Research Grant: PI, NIH-KNS085333A (2013-2018)
Stanford Cancer Institute Bioscience Screening Award PI, Stanford Cancer Institute (2014)
Stanford Spectrum-Medtech Translational Grant (PI), Stanford Spectrum (2014)
Translational Grant Co-PI, CIRM (TRAN1-08522) (2016)
Michael Edwards Resident Teaching Award, Stanford University Department of Neurosurgery (2017)
NIH R01 CA239257-01A1 Optical imaging to improve surgery and targeted therapy in brain tumors, National institutes of health (PI) (2019-2024)
Efficacy of using the Inovivo system to and checkpoint inhibitor treatment in GBM mouse models, Novocure (PI) (2023-2025)
Multi-scale modeling of glioma for prediction of tx response, tx monitoring and tx allocation, NIH R01CA26027101 Co-investigator (PI Gevaert) (May 2021 to April 2026)
Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells in Adults with Recurrent GBM, CIRM CLIN2 Award:Lead Surgeon (PI Thomas) (November 2023 to October 2027)

Professional Education

Residency: Stanford University Dept of Neurosurgery (2011) CA
Internship: Stanford University Dept of Neurosurgery (2005) CA
Medical Education: University of California Davis School of Medicine (2004) CA
Board Certification: American Board of Neurological Surgery, Neurosurgery (2014)
Bachelor of Science, Brown University, Neuroscience (1999)

Contact

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Stanford Neuroscience Health Center 213 Quarry Rd 4th Fl MC 5958 Palo Alto CA 94304 Tel: (650) 497-7777 Fax: (650) 725-0390

Additional Clinical Info

Current Research and Scholarly Interests

1.) My laboratory studies the biology of brain tumors with the goal of developing novel therapeutics for the treatment of malignant brain tumors and translating that research into clinical trials.
2.) My clinical interests include improving surgical techniques for brain tumor surgery, immunotherapy for the treatment of glioblastoma, and novel uses for stereotactic radiosurgery.

Clinical Trials

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme Recruiting
More
This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.
Lead Sponsor
Stanford Investigators
View full details
Study Assessing QBS72S For Treating Brain Metastases Recruiting
More
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic breast cancer with CNS involvement.
Lead Sponsor
Stanford Investigators
View full details
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy Not Recruiting
More
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

Stanford is currently not accepting patients for this trial. For more information, please contact Hari Priya Yerraballa, MBBS, 650-724-9363.
Lead Sponsor
Stanford Investigators
View full details
Surgical Idiopathic Intracranial Hypertension Treatment Trial Not Recruiting
More
Randomized trial of adults (≥18 years old) with idiopathic intracranial hypertension and moderate to severe visual loss without substantial recent treatment who are randomly assigned to (1) medical therapy, (2) medical therapy plus ONSF, or (3) medical therapy plus VPS. The primary outcome is visual field mean deviation change at first of Month 6 (26 weeks) or time of treatment failure of the eligible eye(s), followed by a continuation study to assess time to treatment failure. The determination of eligible eye(s) is based on meeting the eligibility criteria at baseline.

Stanford is currently not accepting patients for this trial. For more information, please contact Mariana Nunez, 650-497-7846.
Lead Sponsor
Stanford Investigators
View full details
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery Recruiting
More
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Lead Sponsor
Stanford Investigators
View full details
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Not Recruiting
More
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.

Stanford is currently not accepting patients for this trial. For more information, please contact Alifia Hasan, 650-721-4088.
Lead Sponsor
Stanford Investigators
- Gordon Li, MD
View full details
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases Not Recruiting
More
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Not Recruiting
More
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Vani Jain, 650-723-1005.
Lead Sponsor
Stanford Investigators
- Gordon Li, MD
View full details
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Not Recruiting
More
This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD

Stanford is currently not accepting patients for this trial. For more information, please contact Sophie Bertrand, 650-723-4467.
Lead Sponsor
Stanford Investigators
View full details
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III Recruiting
More
A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).
Lead Sponsor
Stanford Investigators
View full details
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Not Recruiting
More
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them. It is not yet known whether giving vaccine therapy is more effective with or without bevacizumab in treating glioblastoma multiforme.

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499 .
Lead Sponsor
Stanford Investigators
- Gordon Li, MD
View full details
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas Not Recruiting
More
This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after conventional radiation.

Stanford is currently not accepting patients for this trial. For more information, please contact Christina Huang, 650-723-0574.
Lead Sponsor
Stanford Investigators
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Neurosurgery
  NSUR 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Neurosurgery
  NSUR 280 (Aut, Win, Spr, Sum)
- Graduate Research
  NSUR 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  NSUR 370 (Aut, Win, Spr, Sum)
- Undergraduate Research
  NSUR 199 (Aut, Win, Spr, Sum)

All Publications

Profiles With Related Publications

close
John R. Adler, MD

The Dorothy and Thye King Chan Professor in Neurosurgery, Emeritus
Research Interests
The development and implementation of computerized, image-guided surgical tools to be used during minimally invasive brain operations. The clinical outcome of new technologies, and in particular the application of radiosurgery, for the treatment of brain tumors. The creation of new radiosurgical techniques for a wide array of brain and spine disorders.

288 Total Publications
close
Ash A. Alizadeh, MD/PhD

Moghadam Family Professor
Clinical Focus
Cancer > Lymphoma, Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, Follicular Lymphoma, Diffuse Large-Cell Lymphomas, Leukemia, Hairy Cell, Lymphoma, B-Cell, Marginal Zone, Hodgkin Disease, Medical Oncology
Research Interests
My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

401 Total Publications
close
Steven D. Chang, MD

Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Clinical Focus
Cancer > Neuro Oncology, Brain / Central Nervous System Tumors, Brain / Central Nervous System Tumors - Neuro Oncology, Brain / Central Nervous System Tumors - Neurosurgery, Neurological Surgery, Neurosurgery, Skull Base Tumors , Skull Base Tumors - Head and Neck Surgery, Spinal Cancer, Spinal Cancer - Neurosurgery, Spinal Cancer - Surgery, Acoustic Neuroma, Glioma, Astrocytic, Glioma, Glioblastoma, Glioblastoma with Sarcomatous Component, Astrocytoma, Ependymoma, Medulloblastoma, Meningioma, Intracranial Aneurysm, Carotid Stenosis, Arteriovenous Malformations, Intracranial Arteriovenous Malformations, ACTH-Secreting Pituitary Adenoma, Adenoma, Prolactin-Secreting, Pituitary, Diabetes Insipidus, Pituitary, Growth Hormone-Secreting Pituitary Adenoma, Hypothalamic-Pituitary Neoplasms, Neoplasms, Hypothalamic-Pituitary, PRL-Secreting Pituitary Adenoma, Pituitary ACTH Hypersecretion, Pituitary ACTH-Producing Cells, Pituitary ACTH-Secreting Cells, Pituitary Adenoma, Prolactin-Secreting, Pituitary Adrenocorticotropin-Secreting Cells, Pituitary Apoplexy, Pituitary Diseases, Pituitary FSH Hypersecretion, Pituitary Gland, Pituitary Growth Hormone-Secreting Cells, Pituitary Irradiation, Pituitary Neoplasms, Prolactin-Producing Pituitary Adenoma, Prolactin-Secreting Pituitary Adenoma, Vestibular Schwannoma, brain metastasis, Cyberknife, Radiosurgery, Stereotactic, Stereotactic Techniques, spinal avm, spinal tumor, Spinal Meningioma, spinal schwannoma, Trigeminal Neuralgia, Hemifacial Spasm, Glossopharyngeal Nerve Diseases, AVM (Arteriovenous Malformation) Intracranial, Stroke, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Malignant Primary Brain Tumors, Primary Malignant Brain Tumors, Aneurysm, Cerebral, Acoustic Neuroma, Cerebellopontine Angle, Aneurysm, Anterior Cerebral Artery, Aneurysm, Middle Cerebral Artery, Aneurysm, Posterior Cerebral Artery, Anterior Cerebral Artery Aneurysm, Cerebral Cavernous Hemangioma, Cerebral Hemorrhage, Cerebral Vasculitis, Middle Cerebral Artery Aneurysm, Posterior Cerebral Artery Aneurysm, Vascular Malformations, Brain, Brain Aneurysm, Brain Neoplasms, Brain Revascularization, Neurogenetics, Neuroprotenomics, Neurocutaneous Syndromes, Glomus Tumor, Craniopharyngioma, Pituitary tumor
Research Interests
Clinical research includes studies in the treatment of cerebrovascular disorders, such as aneurysms and AVMs, as well as the use of radiosurgery to treat tumors and vascular malformations of the brain and spine.

Dr. Chang is C0-Director of the Cyberknife Radiosurgery Program.

Dr. Chang is also the head of the The Stanford Neuromolecular Innovation Program with the goal of developing new technologies to improve the diagnosis and treatment of patients affected by neurological conditions.

340 Total Publications
close
Huy M. Do, MD

Professor of Radiology (Neuroimaging and Neurointervention) and, by courtesy, of Neurosurgery and of Otolaryngology - Head & Neck Surgery (OHNS)
Clinical Focus
Interventional Neuroradiology, Endovascular Neurosurgery, Cerebral aneurysm coiling, Brain AVM (arteriovenous malformation), Stroke, Spinal Intervention for pain, Head and neck vascular malformations and anomalies, Interventional Oncology, Pediatric Neuroradiology, Vascular Malformations, Percutaneous Sclerotherapy, Vertebral compression fractures, Trigeminal Neuralgia and facial pain, Neuroradiology

162 Total Publications
close
Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Clinical Focus
Cancer > Neuro Oncology, Neurology - Child Neurology, Neuro-Oncology, Neurology
Research Interests
Clinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.

276 Total Publications
close
Andrew Gentles

Assistant Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science

115 Total Publications
close
Iris C. Gibbs, MD, FACR, FASTRO

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Clinical Focus
Cancer > Radiation Oncology, Brain / Central Nervous System Tumors - Radiation Oncology, Cyberknife/radiosurgery, Acoustic Neuroma , Pediatric brain tumors, Health Equity, Cancer Health Equity, Spinal Cancer - Radiation Oncology, Brain / Central Nervous System Tumors, Pediatric Cancers, Leptommeningeal Disease, Leptommeningeal Disease - Radiation Oncology, Pituitary Adenomas, Pituitary Adenomas - Radiation Oncology, Radiation Oncology, Skull Base Tumors , Skull Base Tumors - Radiation Oncology, Spinal Cancer, Radiosurgery
Research Interests
Dr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.

174 Total Publications
close
Seunggu Jude Han, MD

Clinical Associate Professor, Neurosurgery
Clinical Focus
Neurological Surgery

130 Total Publications
close
Melanie Hayden Gephart

Professor of Neurosurgery and, by courtesy, of Neurology
Clinical Focus
Neurosurgery

155 Total Publications
close
Siddhartha Jaiswal

Assistant Professor of Pathology
Clinical Focus
Transfusion Medicine, Genomics and Molecular Pathology, Anatomic and Clinical Pathology
Research Interests
We identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.

68 Total Publications
close
Michael Lim, M.D.

Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Clinical Focus
Neurosurgery

411 Total Publications
close
Ravi Majeti MD, PhD

Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)
Research Interests
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.

187 Total Publications